Furthermore, abrogation of mutant p53 expression in cancer cells expressing only mutant p53, as often seen in later stages of cancers where the WT p53 allele is lost due to loss-of-heterozygosity [44, 45], resulted in retardation of tumor growth in vivo even when used as a mono-therapy. This evidence concerns the gene TP53 and neoplasm.